Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial.

导出原文传递

翻译打印收藏纠错

作者： Ulf,Näslund ^[1] ; Nawi,Ng ^[2] ; Anna,Lundgren ^[2] ; Eva,Fhärm ^[3] ; Christer,Grönlund ^[4] ; Helene,Johansson ^[2] ; Bernt,Lindahl ^[5] ; Bertil,Lindahl ^[6] ; Kristina,Lindvall ^[2] ; Stefan K,Nilsson ^[7] ; Maria,Nordin ^[8] ; Steven,Nordin ^[8] ; Emma,Nyman ^[9] ; Joacim,Rocklöv ^[5] ; Davide,Vanoli ^[9] ; Lars,Weinehall ^[2] ; Patrik,Wennberg ^[3] ; Per,Wester ^[10] ; Margareta,Norberg ^[2] ; VIPVIZA trial group

作者单位： Heart Centre and Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. Electronic address: ulf.naslund@umu.se. ^[1] Unit of Epidemiology and Global Health, Umeå University, Umeå, Sweden. ^[2] Unit of Family Medicine, Umeå University, Umeå, Sweden. ^[3] Department of Public Health and Clinical Medicine, Department of Radiation Sciences, Umeå University, Umeå, Sweden. ^[4] Unit of Occupational and Environmental Medicine, Umeå University, Umeå, Sweden. ^[5] Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. ^[6] Unit of Physiological Chemistry, Department of Medical Biosciences, Umeå University, Umeå, Sweden. ^[7] Department of Psychology, Umeå University, Umeå, Sweden. ^[8] Heart Centre and Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. ^[9] Unit of Medicine, Umeå University, Umeå, Sweden. ^[10]